ESR1 and breast carcinoma: In addition, HER2+/ER+ breast cancer has recently been shown to be a heterogeneous subgroup, of which patients could benefit from trastuzumab with chemotherapy, combined anti-estrogen and HER2-targeted therapies, or even anti-estrogen alone [8, 12, 13].